Delyon, JulieRabate, ClementineEuvrard, SylvieHarwood, Catherine A.Proby, CharlotteGulec, TulinSeckin, DenizDel Marmol, VeroniqueBouwes-Bavinck, Jan NicoFerrandiz-Pulido, CarlaOcampo, Maria AndreaBarete, StephaneLegendre, ChristopheFrances, CamillePorcher, RaphaelLebbe, Celeste2020-12-242020-12-2420190190-9622http://hdl.handle.net/11727/5180Background: Systemic therapeutic management of post-transplant Kaposi sarcoma (KS) is mainly based on 3 axes: reduction of immunosuppression, conversion to mammalian target of rapamycin (mTOR) inhibitors, chemotherapy, or a combination of these. Objective: To obtain an overview of clinical strategies about the current treatment of KS. Methods: We conducted a multicenter retrospective cohort study including 145 solid organ transplant recipients diagnosed with KS between 1985 and 2011 to collect data regarding first-line treatment and response at 6 months. Results: Overall, 95%, 28%, and 16% of patients had reduction of immunosuppression, conversion to mTOR inhibitor, and chemotherapy, respectively. Patients treated with chemotherapy or mTOR inhibitor conversion were more likely to have visceral KS. At 6 months, 83% of patients had response, including 40% complete responses. Limitations: The retrospective design of the study. Conclusion: Currently available therapeutic options seem to be effective to control KS in most patients. Tapering down the immunosuppressive regimen remains the cornerstone of KS management.enginfo:eu-repo/semantics/closedAccesschemotherapyimmunosuppressionKaposi sarcomamTOR inhibitororgan transplantationpost-transplant malignanciesArticle8124484550004753039000352-s2.0-85067440035